TB006 targets Galectin-3 (GAL-3), a protein found in abnormally high levels in the brains of Alzheimer’s patients. A rise in GAL-3 levels is generally indicative of increased inflammation and associated with worse prognosis.
By binding to GAL-3, TB006 prevents GAL-3 from contributing to plaques or triggering chronic neuroinflammation. This reduces and dissolves the toxic amyloid beta plaques and tau tangles in the brain, which allows neurons to communicate again—potentially reversing some damage and restoring cognitive function. Please watch the following video produced by TrueBinding.
“Several studies have explored the potential of GAL-3 as a biomarker for AD. Elevated levels of GAL-3 have been detected in the serum of AD patients compared to healthy controls. The degree of cognitive impairment, as measured by the Mini-Mental State Examination (MMSE) score, has been found to correlate with GAL-3 serum levels. These findings suggest that GAL-3 could be a valuable biomarker for diagnosing and progressing AD.”
Galectin-3 and Its Association with Dementias: The Potential of TB006 to Reverse Dementias, authored by Arbella Sarkis, MD, and John Bumb.
Its first function is to be a first responder, calling on the immune system to rescue damaged cells. In the right amounts, GAL-3 aides in healing. In addition, it frequently gets overproduced and creates a negative feedback loop associated with many chronic diseases.
Excess GAL-3 in the brain disrupts the immune system, rendering the immune system partially to totally dysfunctional, damaging our brain, and causing dementia of all types and severities.
In scientific terms, GAL-3 contributes to forming toxic oligomers and plaques, disrupting communication between neurons and leading to cognitive decline. GAL-3 overactivation triggers excessive microglial activity and chronic neuroinflammation, further damaging neurons.
TB006 neutralizes GAL-3 and allows the immune system to revitalize and heal the brain, thereby enabling the promotion of improved levels of cognition and other brain functions for individuals.
While there are FDA-approved drugs on the market for the treatment of Alzheimer’s Disease, these drugs are only able to slow the progression of Alzheimer’s Disease, and come with serious unwanted side effects.
Specifically, leading Alzheimer’s drugs, Lequimbi and Kisunla, all show signs of disease slowing after 18 months, but none show signs of disease reversal like TB006. And all three drugs showed ARIA side effects at greater rate than would be expected in normal aging Alzheimer’s patients, compared to no ARIA side effects in TB006 patients.
ARIA = Amyloid Related Imaging Abnormalities. Brain bleeds and brain swelling seen on Brain CT or Brain MRI. Monthly imaging is required for Lequimbi and Kisunla, but not for TB006.
Thus far, TB006 has demonstrated to be safe. TB006 is very selective. Very few medications are contraindicated and its singular selectivity permits it to avoid metabolic interaction. This significantly contributes to its high safety profile. TB006 is administered by an IV drip. In a study of 72 people, only 4 people reported minimal side-effects.
The side effects were:
These are common side-effects for any IV administration.
Patients must qualify for the expanded access program and meet certain requirements.
We may be able to help you find a physician offering this program.
